Literature DB >> 12094199

Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.

C Michael Gibson1, M Imran Dotani, Sabina A Murphy, Susan J Marble, Kent W Dauterman, Andrew D Michaels, J Theodore Dodge.   

Abstract

BACKGROUND AND OBJECTIVES: Slower blood flow in the setting of acute myocardial infarction (MI) has been related to adverse outcomes, but the relationship of coronary blood flow after percutaneous transluminal coronary angioplasty (PTCA) in the setting of acute coronary syndromes to adverse outcomes and restenosis has not been well described. We sought to evaluate the correlates of pre- and post-PTCA coronary blood flow to shed light on potential modifiable determinants.
METHODS: The RESTORE trial (Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis) was a randomized, double-blind, placebo-controlled trial of tirofiban in patients undergoing balloon angioplasty or directional atherectomy within 72 hours of occurrence of either unstable angina pectoris or acute MI. Coronary blood flow was assessed with the corrected TIMI frame count (CTFC), and clinical outcomes were assessed at 30 days.
RESULTS: In addition to tighter and longer minimum lumen diameters (MLDs), the multivariate correlates of slower flow before PTCA also included the presence of thrombus, collaterals, left coronary artery lesion location, acute MI, and >8F catheter size. As well as the above variables, type C and D dissection grades were related to slower post-PTCA CTFC. Death, or the composite of death/MI/coronary artery bypass graft at 30 days, was more frequent among patients with slower post-PTCA CTFCs and those with post-PTCA thrombus. In a multivariate model correcting for reference segment diameter and MLD, the post-PTCA CTFC was an independent predictor of late lumen loss and the follow-up MLD at 6 months. As a single index that integrates functional and anatomical aspects of the post-PTCA results, the ratio of CTFC/MLD was associated with death/MI by 30 days.
CONCLUSIONS: In addition to MLD, variables such as the presence of thrombus, left coronary artery lesion location, and dissection grade also are associated with slower coronary blood flow after PTCA. In turn, post-PTCA CTFCs were an independent predictor of late lumen loss and follow-up MLDs. Furthermore, patients who die or who sustain other adverse cardiac events have slower coronary blood flow and greater thrombus burden after PTCA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12094199     DOI: 10.1067/mhj.2002.123142

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  9 in total

1.  Coronary flow: clinical considerations.

Authors:  D V Cokkinos; A Manginas; V Voudris
Journal:  Heart       Date:  2003-04       Impact factor: 5.994

2.  Current Assessments of the Adequacy of Myocardial Perfusion During Acute MI.

Authors:  Allen Chang; C Michael Gibson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-05

Review 3.  Use of the TIMI frame count in the assessment of coronary artery blood flow and microvascular function over the past 15 years.

Authors:  Vijayalakshmi Kunadian; Caitlin Harrigan; Cafer Zorkun; Alexandra M Palmer; Katherine J Ogando; Leah H Biller; Erin E Lord; Scott P Williams; Michelle E Lew; Lauren N Ciaglo; Jacqueline L Buros; Susan J Marble; William J Gibson; C Michael Gibson
Journal:  J Thromb Thrombolysis       Date:  2008-04-20       Impact factor: 2.300

4.  Integrin targeted therapeutics.

Authors:  Melissa Millard; Srinivas Odde; Nouri Neamati
Journal:  Theranostics       Date:  2011-02-17       Impact factor: 11.556

5.  Advances in Coronary No-Reflow Phenomenon-a Contemporary Review.

Authors:  Ahmadreza Karimianpour; Anbukarasi Maran
Journal:  Curr Atheroscler Rep       Date:  2018-07-05       Impact factor: 5.113

Review 6.  Another view of personalized medicine: optimizing stent selection on the basis of predicted benefit in percutaneous coronary intervention.

Authors:  Neil J Wimmer; Robert W Yeh
Journal:  Trends Cardiovasc Med       Date:  2012-07-28       Impact factor: 6.677

7.  Predictors and outcome of no-reflow post primary percutaneous coronary intervention for ST elevation myocardial infarction.

Authors:  Jawad Mazhar; Mary Mashicharan; Ahmad Farshid
Journal:  Int J Cardiol Heart Vasc       Date:  2015-11-06

8.  The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Mustafa Umut Somuncu; Tunahan Akgun; Mustafa Ozan Cakır; Ferit Akgul; Nail Guven Serbest; Huseyin Karakurt; Murat Can; Ali Riza Demir
Journal:  J Atheroscler Thromb       Date:  2019-04-18       Impact factor: 4.928

9.  Comparison of Intracoronary Epinephrine and Adenosine for No-Reflow in Normotensive Patients With Acute Coronary Syndrome (COAR Trial).

Authors:  Kamran Ahmed Khan; Nadeem Qamar; Tahir Saghir; Jawaid Akbar Sial; Dileep Kumar; Rajesh Kumar; Danish Qayyum; Umamah Yasin; Javed Jalbani; Musa Karim
Journal:  Circ Cardiovasc Interv       Date:  2022-01-10       Impact factor: 6.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.